Evaluation of Peripheral Nerve Stimulation for Acute Treatment of Migraine Pain

NCT ID: NCT04166045

Last Updated: 2021-07-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-06-12

Study Completion Date

2021-04-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Clinical study to determine the responder rate of the TheraNova Migraine Treatment System to that of a sham control treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Episodic Migraine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sham

Treatment at the bicep location

Group Type SHAM_COMPARATOR

Sham Treatment Location

Intervention Type DEVICE

The device applies transcutaneous electrical nerve stimulation to the bicep

Verum

Treatment at the hand location

Group Type ACTIVE_COMPARATOR

Verum Treatment Location

Intervention Type DEVICE

The device applies transcutaneous electrical nerve stimulation to the hand

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sham Treatment Location

The device applies transcutaneous electrical nerve stimulation to the bicep

Intervention Type DEVICE

Verum Treatment Location

The device applies transcutaneous electrical nerve stimulation to the hand

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18-100 years, inclusive
* Diagnosis of episodic migraine with and without aura per International Headache Society diagnostic criteria
* 4-14 migraine days per month
* Ability to provide informed consent
* Demonstrates no contraindication to the use of electrical nerve stimulation
* Capable and willing to follow all study-related procedures

Exclusion Criteria

* Currently pregnant or breastfeeding, pregnant within the past 6 months or intends to become pregnant during the enrollment period
* Diagnosis of chronic migraine or other forms of primary or secondary headache disorders, including medication overuse headache per International Headache Society diagnostic criteria
* Any medical condition that would, in the opinion of the investigator, make the subject ineligible
* Has received botulinum toxin injections within the past 3 months
* Is currently implanted with an electrical and/or neurostimulator devic, including but not limited to cardiac pacemaker or defibrillator, vagal neurostimulator, sacral stimulator, bone growth stimulator, or cochlear implant
* Use of investigational drug/device therapy within the past 4 weeks
* Deemed unsuitable for enrollment in study by the investigator based on subjects' history or physical examination (including bleeding disorders, anticoagulant medications and peripheral neuropathy)
* No changes in preventive medications (or other medications determined to potentially interfere with the study) in the previous 30 days and no intent to change it during the study
Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Theranova, L.L.C.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mayo Clinic

Scottsdale, Arizona, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CRD-01-1282-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

An Acute Migraine Factorial Study
NCT06245902 COMPLETED PHASE2